Getting personal in metastatic melanoma: neoantigen-based vaccines as a new therapeutic strategy2023-10-252023-10-25http://www.nouscom.com/wp-content/uploads/2018/03/artboard-3.pngNouscomhttp://www.nouscom.com/wp-content/uploads/2018/03/artboard-3.png200px200px
D’Alise AM, Scarselli E. Curr Opin Oncol. 2023 Mar
Nouscom is a private oncology company developing next generation immunotherapies, founded in 2015 by an experienced management team that has worked together for many years in previous successful enterprises. Nouscom’s proprietary technology platform harnesses the full power of the immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators.